AC Immune SA (ACIU) Uptrend Detected🚀✅👍💰
Introduction to AC Immune SA (ACIU)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
(NASDAQ:ACIU – Get Rating) had its price objective reduced by SVB Leerink from $15.00 to $10.00 in a report released on Monday, Marketbeat reports. They currently have an outperform rating on the stock.
Several other research analysts have also recently weighed in on the company. StockNews.com cut AC Immune from a hold rating to a sell rating in a research note on Thursday, March 24th. HC Wainwright restated a buy rating and issued a $16.00 price target on shares of AC Immune in a research note on Friday, June 17th.
Shares of NASDAQ:ACIU opened at $3.29 in the July 12th period. The stock has a fifty day simple moving average of $3.20 and a two-hundred day simple moving average of $3.89. The stock has a market capitalization of $274.89 million, a price-to-earnings ratio of -3.10 and a beta of 0.71. AC Immune has a 12-month low of $2.06 and a 12-month high of $12.61.
AC Immune (NASDAQ:ACIU – Get Rating) last announced its quarterly earnings data on Thursday, April 28th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.02). Sell-side analysts predict that AC Immune will post -0.99 EPS for the current fiscal year.
Institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC grew its holdings in shares of AC Immune by 2.3% in the first quarter. Renaissance Technologies LLC now owns 452,490 shares of the company’s stock worth $1,810,000 after acquiring an additional 10,300 shares during the period. BlackRock Inc. grew its holdings in shares of AC Immune by 1.6% in the first quarter. BlackRock Inc. now owns 292,273 shares of the company’s stock worth $1,169,000 after acquiring an additional 4,685 shares during the period. Handelsbanken Fonder AB bought a new stake in shares of AC Immune in the first quarter worth $404,000. Metatron Capital SICAV plc bought a new stake in shares of AC Immune in the fourth quarter worth $218,000. Finally, GSA Capital Partners LLP bought a new stake in shares of AC Immune in the fourth quarter worth $362,000. 26.49% of the stock is owned by institutional investors.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
$AC Immune SA(ACIU)$
AC Immune (ACIU) came out with a quarterly loss of $0.24 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.
A quarter ago, it was expected that this biopharmaceutical company would post a loss of $0.23 per share when it actually produced a loss of $0.25, delivering a surprise of -8.70%.
$AC Immune SA(ACIU)$
AC Immune SA (NASDAQ:ACIU - Get Rating) - Research analysts at SVB Leerink dropped their FY2022 earnings per share (EPS) estimates for AC Immune in a report issued on Monday, August 1st. SVB Leerink analyst M. Goodman now anticipates that the company will post earnings per share of ($1.05) for the year, down from their previous forecast of ($1.03). SVB Leerink currently has a "Outperform" rating and a $10.00 target price on the stock. The consensus estimate for AC Immune's current full-year earnings is ($0.99) per share. SVB Leerink also issued estimates for AC Immune's Q4 2022 earnings at ($0.28) EPS and FY2026 earnings at ($1.10) EPS.